Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis.

Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis. Oncol Rep. 2018 Aug 20;: Authors: Wang J, Yang X, Li R, Wang L, Gu Y, Zhao Y, Huang KH, Cheng T, Yuan Y, Gao S Abstract Long non-coding RNAs (lncRNAs) play critical roles in tumorigenesis and cancer progression. The c-Myc upregulated lncRNA MYU (VPS9D1 antisense RNA1, annotated as VPS9D1-AS1) has been reported in several common types of human cancers, which has revealed that lncRNA MYU could function as either an oncogene or a tumor-suppressor gene in different cancer types. However, the function of lncRNA MYU in prostate cancer remains unknown. In the present study, we demonstrated that lncRNA MYU is significantly upregulated in prostate cancer tissues. MYU knockdown impaired prostate cancer cell growth and migration as shown from cell viability, colony formation, Transwell and wound healing assays. In contrast, MYU overexpression displayed opposite effects. No correlation was noted between MYU and its cognate VPS9D1 expression level. Moreover, lncRNA MYU did not regulate the expression of VPS9D1 either at the mRNA or protein level as detected using qRT-PCR and western blotting assays. Furthermore, lncRNA MYU was able to be transported into the extracellular milieu by means of exosomes, and then promoted adjacent cell proliferation and migration. Mechanistically, lncRNA MYU upregulated c-Myc by competitively binding miR-184 and then induced the proliferati...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Related Links:

Bayer data at ESMO 2019 highlights innovation in cancer researchNew data for larotrectinib on durability of response in patients with TRK fusion cancer to be presented in a poster discussion on September 28 / Data from Bayer's prostate cancer franchise to be presented, including clinical relevance of drug-drug interactions in men with nmCRPC taking darolutamide and real-world data and pain evalutation data in men with mCRPC treated with radium-223 dichloride / New analyses from the Phase II study REGOBONE evaluating the efficacy and safety of regorafenib in patients with rare locally advanced or metastatic relapsed chondro...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news
Patients with non-Hodgkin's lymphoma who received radiation 30 days or less...Read more on AuntMinnie.comRelated Reading: ASTRO: AI predicts side effects from radiation therapy ASTRO: Is hormone therapy after prostate surgery needed? ASTRO: SABR generates immune response to prostate cancer ASTRO: Cervical cancer deaths rise as women's centers close ASTRO: Whole, partial breast RT yield similar cosmetic results
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Publication date: Available online 19 September 2019Source: European UrologyAuthor(s): Nicolai A. Huebner, Shahrokh F. Shariat
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 18 September 2019Source: European UrologyAuthor(s): Mary-Ellen Taplin, Emmanueal S. Antonarakis, Karen J. Ferrante, Kerry Horgan, Brent Blumenstein, Fred Saad, Jun Luo, Johann S. de BonoAbstractBackground: Detection of androgen receptor (AR) splice variant-7 (AR-V7) messenger RNA (mRNA) in circulating tumor cells (CTCs) is associated with a suboptimal response to abiraterone and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). Galeterone inhibits CYP17 and AR, and induces AR protein degradation. We hypothesized that galeterone would be clinically superior to enzalu...
Source: European Urology - Category: Urology & Nephrology Source Type: research
DiscussionPCOs measured in studies of mpMRI or MRI-guided biopsy thus far have mostly been physical outcomes, with some evidence that MRI tests are associated with less frequent adverse outcomes compared with transrectal ultrasound biopsy. There was very little evidence for the effect of mpMRI and MRI-guided biopsy on emotional, cognitive, social, or behavioral outcomes.
Source: Journal of the American College of Radiology - Category: Radiology Source Type: research
Condition:   Prostate Cancer Interventions:   Drug: enzalutamide;   Drug: enzalutamide Placebo;   Drug: digoxin;   Drug: rosuvastatin Sponsors:   Astellas Pharma Global Development, Inc.;   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Second interim analysis from the Phase 3 SPARTAN study reporting updated overall survival results in patients with non-metastatic castration-resistant prostate cancer treated with ERLEADA ® (apalutamide)Patient-reported outcomes from the Phase 3 TITAN study evaluating ERLEADA® in patients with metastatic castration-sensitive prostate cancer Interim analysis from the Phase 2 GALAHAD study evaluating niraparib in the treatment of patients with metastatic castration-resistant prostate cancer and biallelic DNA-repair gene defects, featured as late-breaking abstract
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Complementary and alternative medicine (CAM) use is increasing among men with prostate cancer, but an expert advises steering patients away from vitamins.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Phase 3 TITAN is the first registrational study to achieve statistical significance in dual primary endpoints of overall survival and radiographic progression-free survival in patients with mCSPC regardless of extent of disease
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
The androgen receptor inhibitor, which is already approved for use in nonmetastatic castration-resistant prostate cancer, has now been approved for a different patient population.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer | Cancer & Oncology | Genetics | Prostate Cancer | Study